Harvard Bioscience, Inc.
HBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0.7% | -6.1% | -11.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 58.4% | 50.7% | 56% | 57.1% |
| EBITDA | $0 | $0 | -$0 | $0 |
| % Margin | 5.6% | 0.8% | -222% | 13% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -6% | -11.2% | -231.2% | 0.1% |
| EPS Diluted | -0.03 | -0.052 | -1.14 | 0 |
| % Growth | 41.7% | 95.5% | -285,100% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |